Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10825MR)

This product GTTS-WQ10825MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10825MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7869MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ13661MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ11555MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ460MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ12409MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ2089MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ1960MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ9474MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW